Infliximab population pharmacokinetic modelling in patients with Inflammatory Bowel Disease (IBD): Patient factors influencing infliximab pharmacokinetics

被引：0
|
作者：
Guardiola, J. [1 ]
Rodriguez-Alonso, L. [1 ]
Santacana, E. [2 ]
Padulles, N. [2 ]
Colom, H. [3 ]
Padulles, A. [2 ]
Arajol, C. [1 ]
Ruiz-Cerulla, A. [1 ]
Cobo, S. [2 ]
Bas, J. [4 ]
Climent, J. [4 ]
Morandeira, F. [4 ]
Rodriguez-Moranta, F. [1 ]
机构：
[1] Hosp Univ Bellvitge, Gastroenterol, Lhospitalet De Llobregat, Spain
[2] Hosp Univ Bellvitge, Pharm, Lhospitalet De Llobregat, Spain
[3] Univ Barcelona, Sch Pharm, Pharmacokinet, Barcelona, Spain
[4] Hosp Univ Bellvitge, Immunol, Lhospitalet De Llobregat, Spain
来源：
JOURNAL OF CROHNS & COLITIS | 2015年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P453
引用
收藏
页码：S306 / S307
页数：2
相关论文
共 50 条
  • [21] Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease
    Amy Hemperly
    Niels Vande Casteele
    Clinical Pharmacokinetics, 2018, 57 : 929 - 942
  • [22] Thiopurine Use and Persistence on Infliximab Therapy for Inflammatory Bowel Disease (IBD)
    Haynes, Kevin
    Curtis, Jeffery R.
    Chen, Lang
    Osterman, Mark T.
    Saag, Ken G.
    Lewis, James D.
    GASTROENTEROLOGY, 2011, 140 (05) : S781 - S781
  • [23] Thiopurine Use and Persistence on Infliximab Therapy for Inflammatory Bowel Disease (IBD)
    Haynes, Kevin
    Lewis, James D.
    Osterman, Mark T.
    Chen, Lang
    Kenneth, Saag
    Curtis, Jeffery R.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S71 - S71
  • [24] Infliximab in inflammatory bowel disease
    Papamichael, Konstantinos
    Lin, Steve
    Moore, Matthew
    Papaioannou, Garyfallia
    Sattler, Lindsey
    Cheifetz, Adam S.
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2019, 10
  • [25] Detection of Anti Infliximab Antibodies in Patients with Inflammatory Bowel Disease (IBD) in the Presence of Infliximab by Homogeneous Liquid Phase Anti Infliximab Mobility Shift Assay
    Eser, Alexander
    Primas, Christian
    Shringarpure, Reshma
    Hauenstein, Scott
    Wang, Shui Long
    Reinisch, Walter
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S657 - S657
  • [26] Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients
    Eberl, Anja
    Huoponen, Saara
    Pahikkala, Tapio
    Blom, Marja
    Arkkila, Perttu
    Sipponen, Taina
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2017, 52 (12) : 1348 - 1353
  • [27] The effect of infliximab dose escalation in inflammatory bowel disease patients with antibodies to infliximab
    Tun, Gloria S. Z.
    Robinson, Kerry
    Marshall, Laura
    Wright, Alison
    Thompson, Laura
    Wild, Graeme
    Sargur, Ravishankar
    Brooks, Alenka J.
    Hale, Melissa F.
    Chew, Thean S.
    Lobo, Alan J.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 34 (03) : 295 - 301
  • [28] THE EFFECT OF INFLIXIMAB DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH ANTIBODIES TO INFLIXIMAB
    Tun, Gloria S. Z.
    Marshall, Laura
    Thompson, Laura
    Campbell, Rebecca
    Hale, Melissa F.
    Chew, Thean S.
    Brooks, Alenka J.
    Robinson, Kerry
    Lobo, Alan J.
    GUT, 2019, 68 : A61 - A62
  • [29] Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
    Nanda, Kavinderjit S.
    Cheifetz, Adam S.
    Moss, Alan C.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 (01): : 40 - 47
  • [30] Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease
    Nanja C. Bevers
    Ron J. Keizer
    Dennis R. Wong
    Arta Aliu
    Marieke J. Pierik
    Luc J. J. Derijks
    Patrick F. van Rheenen
    Clinical Pharmacokinetics, 2024, 63 : 529 - 538
12345